智飞生物
(300122)
| 流通市值：195.88亿 | | | 总市值：331.54亿 |
| 流通股本：14.14亿 | | | 总股本：23.94亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,538,667,867.54 | 4,023,767,992.3 | 2,150,185,419.45 | 8,958,435,384.96 |
| 营业收入 | 6,538,667,867.54 | 4,023,767,992.3 | 2,150,185,419.45 | 8,958,435,384.96 |
| 二、营业总成本 | 7,353,155,696.88 | 4,837,680,346.44 | 2,218,602,295.96 | 12,358,235,775.89 |
| 营业成本 | 4,930,041,438.22 | 3,296,137,903.64 | 1,523,243,311.14 | 8,255,694,581.97 |
| 税金及附加 | 28,980,607.27 | 24,096,882.2 | 11,784,843.25 | 68,388,751.02 |
| 销售费用 | 1,216,163,780.97 | 746,971,730.41 | 293,704,514.71 | 2,386,453,403.38 |
| 管理费用 | 273,028,852.34 | 181,332,721.08 | 90,292,568.41 | 413,645,708.87 |
| 研发费用 | 669,452,363.7 | 427,562,770 | 213,682,660.68 | 932,298,240.66 |
| 财务费用 | 235,488,654.38 | 161,578,339.11 | 85,894,397.77 | 301,755,089.99 |
| 其中:利息费用 | 241,635,465.35 | 164,206,448.08 | 85,870,470.48 | 331,042,166.52 |
| 其中:利息收入 | 11,226,088.67 | 6,585,390.87 | 3,256,388.4 | 24,654,559.37 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | - | -14,221,154.72 |
| 加:投资收益 | -2,314,595.19 | -2,314,595.19 | -2,314,595.19 | 13,903.16 |
| 资产处置收益 | 3,799.8 | 3,107.74 | 3,107.74 | 5,880,932.83 |
| 资产减值损失(新) | 210,261,867.51 | 190,587,294.03 | -26,742,492.01 | -13,618,428,805.9 |
| 信用减值损失(新) | -276,017,325.68 | -359,588,236.34 | -353,558,778.64 | -509,730,029.51 |
| 其他收益 | 24,440,681.26 | 16,967,543.52 | 9,034,335.57 | 76,291,357.49 |
| 四、营业利润 | -858,113,401.64 | -968,257,240.38 | -441,995,299.04 | -17,459,994,187.58 |
| 加:营业外收入 | 123,059.97 | 100,838.58 | 650 | 113,677.12 |
| 减:营业外支出 | 16,788,717.77 | 16,644,801.42 | 2,911,009.63 | 32,781,880.29 |
| 五、利润总额 | -874,779,059.44 | -984,801,203.22 | -444,905,658.67 | -17,492,662,390.75 |
| 减:所得税费用 | -169,758,555.09 | -164,463,615.54 | -51,202,266.79 | -2,747,397,812.29 |
| 六、净利润 | -705,020,504.35 | -820,337,587.68 | -393,703,391.88 | -14,745,264,578.46 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -705,020,504.35 | -820,337,587.68 | -393,703,391.88 | -14,745,264,578.46 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -683,252,251.48 | -808,508,103.45 | -388,316,279 | -14,723,152,851.99 |
| 少数股东损益 | -21,768,252.87 | -11,829,484.23 | -5,387,112.88 | -22,111,726.47 |
| 扣除非经常损益后的净利润 | -687,092,571.68 | -806,398,522.92 | -391,344,217.71 | -14,743,796,350.21 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.29 | -0.34 | -0.16 | -6.15 |
| (二)稀释每股收益 | -0.29 | -0.34 | -0.16 | -6.15 |
| 九、综合收益总额 | -705,020,504.35 | -820,337,587.68 | -393,703,391.88 | -14,745,264,578.46 |
| 归属于母公司股东的综合收益总额 | -683,252,251.48 | -808,508,103.45 | -388,316,279 | -14,723,152,851.99 |
| 归属于少数股东的综合收益总额 | -21,768,252.87 | -11,829,484.23 | -5,387,112.88 | -22,111,726.47 |
| 公告日期 | 2026-10-27 | 2026-08-29 | 2026-04-28 | 2026-04-28 |
| 审计意见(境内) | | | | 标准无保留意见 |